Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precise treatment of Crohn's disease with infliximab based on genetics and intestinal microbiota
ChiCTR-RPC-16009388Phase 4Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab in Crohn's disease (2 arms), sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Efficacy of infliximab, Change of gene expression and 2 more. Started Nov 2016; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR-RPC-16009388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RPC-16009388.